Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression

Recent insights into the molecular and cellular mechanisms underlying cancer development have revealed that immune cells functionally regulate epithelial cancer development and progression. Moreover, accumulated clinical and experimental data indicate that the outcome of an immune response toward an evolving breast neoplasm is largely determined by the type of immune response elicited. Acute tumor-directed immune responses involving cytolytic T lymphocytes appear to protect against tumor development, whereas immune responses involving chronic activation of humoral immunity, infiltration by Th2 cells, and protumor-polarized innate inflammatory cells result in the promotion of tumor development and disease progression. Herein we review this body of literature and summarize important new findings revealing the paradoxical role of innate and adaptive leukocytes as regulators of breast carcinogenesis.

[1]  M. Smyth NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. , 2001, International immunology.

[2]  L. Coussens,et al.  Immune cells as anti‐cancer therapeutic targets and tools , 2007, Journal of cellular biochemistry.

[3]  L. Coussens,et al.  Humoral immunity, inflammation and cancer. , 2007, Current opinion in immunology.

[4]  L. Zitvogel,et al.  Links between innate and cognate tumor immunity. , 2007, Current opinion in immunology.

[5]  A. Saraux,et al.  B-cell: a logical target for treatment of rheumatoid arthritis. , 2007, Clinical and experimental rheumatology.

[6]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Pollard,et al.  Macrophages regulate the angiogenic switch in a mouse model of breast cancer. , 2006, Cancer research.

[8]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[9]  Michael Karin,et al.  Intracellular pattern recognition receptors in the host response , 2006, Nature.

[10]  M. Karin Nuclear factor-κB in cancer development and progression , 2006, Nature.

[11]  Wanjun Chen Dendritic cells and (CD4+)CD25+ T regulatory cells: crosstalk between two professionals in immunity versus tolerance. , 2006, Frontiers in bioscience : a journal and virtual library.

[12]  H. Lyerly,et al.  Dendritic Cell-Based Immunotherapy , 2006, International reviews of immunology.

[13]  L. Coussens,et al.  The inflammatory tumor microenvironment and its impact on cancer development. , 2006, Contributions to microbiology.

[14]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[15]  F. F. Madrid,et al.  Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. , 2005 .

[16]  A. Banham,et al.  Cutting Edge: Direct Suppression of B Cells by CD4+CD25+ Regulatory T Cells1 , 2005, The Journal of Immunology.

[17]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[18]  Susan Holmes,et al.  Profile of Immune Cells in Axillary Lymph Nodes Predicts Disease-Free Survival in Breast Cancer , 2005, PLoS medicine.

[19]  Andreas Radbruch,et al.  Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells , 2005, European journal of immunology.

[20]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[21]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[22]  A. Mantovani,et al.  Smoldering and polarized inflammation in the initiation and promotion of malignant disease. , 2005, Cancer cell.

[23]  C. Punt,et al.  Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes , 1994, Cancer Immunology, Immunotherapy.

[24]  S. Oluwole,et al.  Breast cancer in women with HIV/AIDS: Report of five cases with a review of the literature , 2005, Journal of surgical oncology.

[25]  F. Quismorio,et al.  Circulating anti-tumor and autoantibodies in breast carcinoma: Relationship to stage and prognosis , 2005, Breast Cancer Research and Treatment.

[26]  R. Moss,et al.  Th1/Th2 cells in inflammatory disease states: therapeutic implications , 2004, Expert opinion on biological therapy.

[27]  B. Fingleton,et al.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. , 2004, Cancer cell.

[28]  J. Myśliwska,et al.  CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. , 2004, Clinical immunology.

[29]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[30]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[31]  P. Allavena,et al.  Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. , 2004, European journal of cancer.

[32]  N. Funel,et al.  Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma , 2004, Journal of Clinical Pathology.

[33]  D. Bar-Sagi,et al.  Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. , 2004, Cancer cell.

[34]  J. Ceuppens,et al.  Regulation of the immune response by prostaglandins , 1983, Journal of Clinical Immunology.

[35]  J. Pollard,et al.  Macrophages: modulators of breast cancer progression. , 2004, Novartis Foundation symposium.

[36]  J. Pollard Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[37]  D. Page,et al.  Routinely available indicators of prognosis in breast cancer , 2004, Breast Cancer Research and Treatment.

[38]  S. Cingarlini,et al.  Derangement of immune responses by myeloid suppressor cells , 2004, Cancer Immunology, Immunotherapy.

[39]  F. Shi,et al.  Relative paradigms between autoantibodies in lupus and autoantibodies in cancer , 2003, Clinical and experimental immunology.

[40]  E. Hersh,et al.  Naturally occurring B-cell responses to breast cancer , 2003, Cancer Immunology, Immunotherapy.

[41]  Umberto Veronesi,et al.  A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. , 2003, The New England journal of medicine.

[42]  H. Hirai,et al.  Human CD4+ CD25+ regulatory T cells suppress NKT cell functions. , 2003, Cancer research.

[43]  M. McHeyzer-Williams,et al.  B cells as effectors. , 2003, Current opinion in immunology.

[44]  D. Ribatti,et al.  Tumor vascularity and tryptase‐positive mast cells correlate with a poor prognosis in melanoma , 2003, European journal of clinical investigation.

[45]  Jean Kanitakis,et al.  Skin cancers after organ transplantation. , 2003, The New England journal of medicine.

[46]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[47]  J. Nyhus,et al.  Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. , 2002, Cancer research.

[48]  P. Hogarth Fc receptors are major mediators of antibody based inflammation in autoimmunity. , 2002, Current opinion in immunology.

[49]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[50]  L. Kaer,et al.  IFN-γ–mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramide , 2002 .

[51]  L. Adorini,et al.  Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation , 2002, Journal of Neuroimmunology.

[52]  C. Boshoff,et al.  Aids-related malignancies , 2002, Nature Reviews Cancer.

[53]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[54]  R. Cardiff,et al.  Mammary Disease Mice Model Premalignant Polyoma Middle-T Transgenic Updated Version , 2001 .

[55]  J. Fung,et al.  De novo malignancies after liver transplantation: A major cause of late death , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[56]  P. Telleman,et al.  Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. , 2001, Cancer research.

[57]  M. Schymura,et al.  Cancer incidence in New York State acquired immunodeficiency syndrome patients. , 2001, American journal of epidemiology.

[58]  L. Benítez-Bribiesca,et al.  The Role of Mast Cell Tryptase in Neoangiogenesis of Premalignant and Malignant Lesions of the Uterine Cervix , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[59]  D. Gabrilovich,et al.  Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells1 , 2001, The Journal of Immunology.

[60]  Andrew V. Nguyen,et al.  Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.

[61]  L. Coussens,et al.  Inflammatory Cells and Cancer , 2001, The Journal of experimental medicine.

[62]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[63]  Nicholas R. English,et al.  Increased Production of Immature Myeloid Cells in Cancer Patients: A Mechanism of Immunosuppression in Cancer1 , 2001, The Journal of Immunology.

[64]  J. V. Ravetch,et al.  IgG Fc receptors. , 2001, Annual review of immunology.

[65]  G. Capitanio,et al.  Sentinel node biopsy in breast cancer. , 2003, Breast.

[66]  F. Fallarino,et al.  Spontaneous Rejection of Poorly Immunogenic P1.HTR Tumors by Stat6-Deficient Mice1 , 2000, The Journal of Immunology.

[67]  M. Grusby,et al.  Cutting Edge: STAT6-Deficient Mice Have Enhanced Tumor Immunity to Primary and Metastatic Mammary Carcinoma1 , 2000, The Journal of Immunology.

[68]  H. Schreiber,et al.  Immunological enhancement of primary tumor development and its prevention. , 2000, Seminars in cancer biology.

[69]  Christopher A. Lazarski,et al.  Enhanced Growth of Primary Tumors in Cancer-Prone Mice after Immunization against the Mutant Region of an Inherited Oncoprotein , 2000, The Journal of experimental medicine.

[70]  H. Kojima,et al.  Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. , 2000, The European respiratory journal.

[71]  N. Chiorazzi,et al.  Accumulation of Clonally Related B Lymphocytes in the Cerebrospinal Fluid of Multiple Sclerosis Patients1 , 2000, The Journal of Immunology.

[72]  J. Nyhus,et al.  Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. , 1999, Neoplasia.

[73]  F. Fallarino,et al.  Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. , 1999, Journal of immunology.

[74]  D. Hanahan,et al.  Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. , 1999, Genes & development.

[75]  J. Okamura,et al.  Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis , 1999, Gastric Cancer.

[76]  J. Finke,et al.  Where have all the T cells gone? Mechanisms of immune evasion by tumors. , 1999, Immunology today.

[77]  C. Berek,et al.  Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. , 1999, Journal of immunology.

[78]  B. Fox,et al.  Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. , 1998, Journal of immunology.

[79]  C. Berek,et al.  Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome. , 1998, The Journal of clinical investigation.

[80]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[81]  Makiko Kobayashi,et al.  A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. , 1998, Journal of immunology.

[82]  Autoantibodies, autoimmunity and cancer (review). , 1998, Oncology reports.

[83]  D. Braun,et al.  Functional analysis of tumor-infiltrating leukocytes in breast cancer patients. , 1998, The Journal of surgical research.

[84]  S. Ménard,et al.  High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  S. Romagnani,et al.  The Th1/Th2 paradigm. , 1997, Immunology today.

[86]  G. Halliday,et al.  T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. , 1997, The Journal of investigative dermatology.

[87]  J. Norton,et al.  IL-12 induces T helper 1-directed antitumor response. , 1997, Journal of immunology.

[88]  L. Happerfield,et al.  Angiogenesis and inflammation in ductal carcinoma in situ of the breast , 1997, The Journal of pathology.

[89]  M. Kaufman,et al.  Concurrent immunohistochemical staining of tumor-infiltrating lymphocytes and carcinoma-associated T (Thomsen-Friedenreich)/Tn antigens in human breast carcinoma. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[90]  C. Casciani,et al.  Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression , 1996, Cancer Immunology, Immunotherapy.

[91]  B. Griffith,et al.  Solid tumors after heart transplantation: lethality of lung cancer. , 1995, The Annals of thoracic surgery.

[92]  G. Opelz,et al.  Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation , 1995, The Lancet.

[93]  M. Emoto,et al.  Functions of T-cell subsets and cytokines in mycobacterial infections. , 1995, The European respiratory journal. Supplement.

[94]  Eero Pukkala,et al.  Cancer risk after renal transplantation in the nordic countries, 1964–1986 , 1995, International journal of cancer.

[95]  V. Pistoia,et al.  Relationships Between B Cell Cytokine Production in Secondary Lymphoid Follicles and Apoptosis of Germinal Center B Lymphocytes , 1995, Stem cells.

[96]  M. Prummel,et al.  Molecular cloning and characterization of genes for antibodies generated by orbital tissue-infiltrating B-cells in Graves' ophthalmopathy. , 1994, The Journal of clinical endocrinology and metabolism.

[97]  D. Parker T cell-dependent B cell activation. , 1993, Annual review of immunology.

[98]  J. Raus,et al.  Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. , 1992, Anticancer research.

[99]  V. Kosma,et al.  Lymphocyte infiltrates as a prognostic variable in female breast cancer. , 1992, European journal of cancer.

[100]  A. Campbell,et al.  Flow cytometric analysis of tumour infiltrating lymphocyte activation and tumour cell MHC class I and II expression in breast cancer patients. , 1992, Cancer letters.

[101]  R. Stout,et al.  Antigen-specific activation of effector macrophages by IFN-gamma producing (TH1) T cell clones. Failure of IL-4-producing (TH2) T cell clones to activate effector function in macrophages. , 1989, Journal of immunology.

[102]  N. Smorodinsky,et al.  The immune system during the precancer period: naturally-occurring tumor reactive monoclonal antibodies and urethane carcinogenesis. , 1988, Immunology letters.

[103]  H. David,et al.  Rudolf Virchow and modern aspects of tumor pathology. , 1988, Pathology, research and practice.

[104]  B. Morton,et al.  Monoclonal antibody-defined phenotypes of regional lymph node and peripheral blood lymphocyte subpopulations in early breast cancer. , 1986, Cancer research.

[105]  E. Sánchez‐Cantalejo,et al.  Correlation of Histologic Grade and Lymph Node Status with Some Histopathologic Discriminants in Breast Cancer , 1986, Tumori.

[106]  Masakatsu Imamura,et al.  Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: An immunoperoxidase study with anti‐human t‐ and b‐cell sera , 1982 .

[107]  J. Ellner Suppressor cells of man. , 1981, Clinical immunology reviews.

[108]  Y. Lee,et al.  Ductular carcinoma of the breast. Serum antibodies to tumor‐associated antigens , 1979, Cancer.

[109]  M. Wernicke Quantitative morphologic assessment of immunoreactivity in regional lymph nodes of patients with carcinoma of the breast. , 1975, Surgery, gynecology & obstetrics.

[110]  N. Kaliss Immunological enhancement of tumor homografts in mice: a review. , 1958, Cancer research.

[111]  G. Snell Incompatibility reactions to tumor homotransplants with particular reference to the role of the tumor; a review. , 1957, Cancer research.